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Abstract
Objectives Depression is common in patients with diabetes,
and the use of antidepressants may impair glycaemic
control. We assessed the association between antidepressant
use and hyper- and hypoglycaemia.
Methods Based on spontaneous reports listed in the World
Health Organization (WHO) Adverse Drug Reaction
Database, a case-control study was conducted. The study
base consisted of all adverse drug reactions (ADRs)
ascribed to antidepressants, antipsychotics and benzodiaze-
pines between 1969 and 2005. Cases were defined as
reported ADRs classified as hyper- or hypoglycaemia and
separated in different study populations. All other reports
were considered as controls. Exposure to antidepressants
was the primary determinant investigated. Benzodiazepines
and antipsychotics were chosen as reference groups.
Potential confounding factors, namely, age, gender, use of
antidiabetic medication, use of hyper- or hypoglycaemia-
inducing comedication and reporting year, were determined
on the index date. Multivariate logistic regression was used
to evaluate the strength of the association, which was
expressed as reporting odds ratios (RORs) with 95%
confidence intervals (95% CI).
Results Overall, the use of antidepressants was associated
with hyperglycaemia [ROR 1.52 (95% CI: 1.20–1.93)] and
of hypoglycaemia [ROR 1.84 (95% CI: 1.40–2.42)]. The
association with hyperglycaemia was most pronounced
for antidepressants with affinity for the 5-HT2c receptor,
histamine-1 receptor and norepinephrinic (NE) reuptake
transporter. The association with hypoglycaemia was most
pronounced for antidepressants with affinity for the sero-
tonin reuptake transporter.
Conclusion The results of this study strengthen the findings
in individual case reports that the use of antidepressants is
associated with disturbances in glucose homeostasis.
Keywords Hyperglycaemia.Hypoglycaemia.
Antidepressive agents.AdversedrugReaction
reporting systems.WHO
Introduction
The use of psychotropic agents has been related to
disturbances in glucose homeostasis. Antipsychotics in
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pine and olanzapine, can cause hyperglycaemia, diabetes
mellitus type 2, and other metabolic disturbances [2, 3].
Antidepressants may also interfere with blood glucose metab-
olism, paradoxically increasing the risk of both hyper- and
hypoglycaemia [4–7]. However, evidence on the association
of antidepressant use and impaired glucose homeostasis is
more scarce and mainly originates from case reports and
short-term trials with selected and small group of patients
with comorbid diabetes mellitus.
Antidepressant use is common in patients with diabetes
mellitus; several studies revealed that the risk of depression
is twice as high among adults with chronic diabetes mellitus
compared with the general population [8]. If antidepres-
sants indeed interfere with glucose homeostasis in patients
with diabetes mellitus, then this could further complicate
glycaemic control, which is a limiting factor to prevent or
delay microvascular complications [9–12] in the long term.
In order to contribute to the evidence base on the asso-
ciation between the use of antidepressants and hyper- and
hypoglycaemia, we carried out a case-control study based on
spontaneous reports of adverse drug reactions (ADRs) in the
database of the international pharmacovigilance programme
of the World Health Organization (WHO ADR database). In
addition, we wanted to elucidate whether specific pharma-
cological properties could explain a potential influence on
glucose homeostasis.
Materials and methods
Setting
The study was conducted within the database of the WHO
Uppsala Monitoring Center (WHO UMC), Sweden. The
WHO UMC receives summary clinical reports about individ-
ual suspected adverse reactions to pharmaceutical products
submitted through National Pharmacovigilance Centers by 82
countries around the world, and the reports are heterogeneous
with regards to source, documentation and relationship
likelihood. The reports are submitted in an electronic format
and stored in a central database: Vigibase. The programme
wasestablishedin1968.TheWHOdatabaseholds3.7million
records, making itthe world’s largestdatabase ofspontaneous
ADRs. Details available about suspected ADRs are age,
gender, reporting date, country, nature of the ADR, suspected
drug(s), concomitantly used drug(s) and interacting drug(s).
Drugs and suspected ADRs are respectively classified
according to the Anatomical Therapeutic Chemical (ATC)
classification system and the WHO Adverse Reaction
Terminology(WHO-ART).Allpatientinformationisprovided
anonymously [13].
Study design and population
A nested case control design was used to evaluate the
association between the use of antidepressants and hyper-
and hypoglycaemia. The base cohort consisted of all reports
of ADRs in association with antidepressants, antipsychotics
or benzodiazepines between January 1969 and January
2005. Reports were only included when data on gender
were available and the patients were 18 years or older.
Hyper- and hypoglycaemic reactions were separated in two
different study populations. Cases were defined as reported
ADRs classified as hyper- or hypoglycaemia. Hyperglycemia
cases included all reports with preferred-Level terms diabetes
mellitus, diabetes mellitus aggravated, diabetes mellitus
reactivated, hyperglycaemia, ketosis, glucose intolerance
abnormal, diabetic or glycosuria. Hypoglycaemia cases includ-
ed all reports with preferred-level terms hypoglycaemia, hypo-
glycaemic reaction and coma hypoglycaemic. All reports
containing other adverse event terms were considered as
controls.
Exposure
Exposure to antidepressants was the primary determinant
investigated and was defined as the reporting of anti-
depressants as a suspected, interacting or concomitant drug
for an ADR. Exposure to antidepressants was further sub-
classified into four clusters based upon pharmacological
binding properties of six common transporter or receptor
sites: the 5-HT (serotonin) reuptake transporter, norepi-
nephrine reuptake transporter, M3 receptor, H1 receptor, α1
receptor and 5-HT2c receptor [14]. When two different
antidepressants were reported in the same report they could
not be classified into one of the four clusters, and the report
was classified into a fifth classification category: two
antidepressants. Benzodiazepines were chosen as a negative
comparator group for hypo- and hyperglycaemia because
the use of benzodiazepines has not been associated with
hyper- or hypoglycaemia, and patients using benzodiaze-
pines are more likely to have similar baseline characteristics
as patients using antidepressants because both benzodiaze-
pines and antidepressants belong to the group of psycho-
tropic agents. Antipsychotics (which are associated with
a higher risk of hyperglycaemia but not hypoglycaemia [2,
3]) were chosen as a positive comparator group for
hyperglycaemia and as a negative comparator group for
hypoglycaemia. Exposure to antipsychotics and benzodia-
zepines was defined as the reporting of respectively anti-
psychotics and benzodiazepines as a suspected, interacting
or concomitant drug for an ADR. Reports with two or more
types of drugs (antidepressant, benzodiazepine or anti-
psychotic agent) within the same report were excluded.
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The following covariates were studied to adjust for potential
confounding: age, gender, use of diabetic medication, use of
hyper- or hypoglycaemia-inducing comedication and report-
ing year. The use of antidiabetic medication and of hyper- or
hypoglycaemia-inducing comedication was defined as the
reporting of one of these drugs as a suspected, interacting or
concomitant drug for an ADR. Hyper- and hypoglycaemia-
inducing comedications were identified by a search in
literature. For details we refer to references [15–17].
Data analysis
For both cases and controls, the prevalence of each char-
acteristic on the index date (reporting date of the ADR) was
determined. Student’s t test was performed to assess the
significance of differences in the mean of continuous vari-
ables between cases and controls. Differences in the
proportions of categorical variables of the baseline charac-
teristics between cases and controls were tested for sig-
nificance by unconditional logistic regression and expressed
as p values. The strength of the association between the use
of antidepressants or antipsychotics and hypo- or hyper-
glycaemia was evaluated with unconditional logistic regres-
sion analysis and expressed as reporting odds ratios (ROR)
with 95% confidence intervals (95% CI). Besides age and
gender, covariates were included in the unconditional
regression model if they were either independently signifi-
cantly associated with hypo- or hyperglycaemia or induced a
change in the crude OR for current use of antidepressants of
at least 10% [18]. Unless antidiabetic medication fulfilled the
conditions as a covariate to correct for in the logistic model,
we excluded this antidiabetic medication as a covariate from
analysis because information about diabetic comedication
was incomplete. Exclusion of antidiabetic medication from
the model, however, did not significantly change the primary
outcome. All statistical calculations were carried out with the
SPSS statistical package (version 12.0).
Results
Hyperglycaemia
The base cohort consisted of 192,292 reports. From this
cohort, 1,953 (1.02%) reports were identified as cases and
190,339 (98.98%) as controls. Table 1 describes details of
demographic and medical characteristics of the study
population. Mean age was statistically different among the
cases and the controls. Cases were more frequently male
than were controls, and the use of diabetic medication, use
of hyper- or hypoglycaemia-inducing comedication was
more frequently reported in cases than in controls. Finally,
Table 1 Baseline characteris-
tics of the hyperglycaemia
study population
Risk factor Cases
(hyperglycaemia)
(n=1,953)
Controls (no
hyperglycaemia)
(n=190,339)
P value
Mean age (years) 45.1 47.3 <0.001
Age category
18–35 years 568 (29.1%) 57,220 (30.1%) Reference
36–55 years 958 (49.1%) 75,546 (39.7%) <0.001
>55 years 427 (21.9%) 57,573 (30.2%) <0.001
Gender
Male 1,138 (58.3%) 76,024 (39.9%) Reference
Female 815 (41.7%) 114,315 (60.1%) <0.001
Diabetic comedication
No diabetic comedication 1,648 (84.4%) 187,674 (98.6%) Reference
Insulin 150 (7.7%) 923 (0.5%) <0.001
Oral antidiabetics 131 (6.7%) 1,647 (0.9%) <0.001
Oral antidiabetics + insulin 24 (1.2%) 95 (0.0%) <0.001
Hypo- or hyperglycaemia-inducing comedication use
No comedication associated with hypo- or
hyperglycaemia
1,610 (82.4%) 150,112 (78.9%) Reference
Comedication associated with hypo-
or hyperglycaemia
343 (17.6%) 40,227 (21.1%) <0.001
Reporting year
1968–1990 92 (4.7%) 36,644 (19.3%) Reference
1991–2000 713 (36.5%) 102,266 (53.7%) <0.001
2001–2005 1,148 (58.8%) 51,429 (27.0%) <0.001
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2001–2005 than were the controls. Table 2 shows the
association between the use of antidepressants and hyper-
glycaemia. Overall, use of antidepressants was associated
with hyperglycaemia [RORadj: 1.52 (95% CI: 1.20–1.93)].
Looking at classification according to the pharmacological
properties of antidepressants, antidepressants from cluster 1
(sertraline, fluvoxamine, paroxetine, venlafaxine, fluoxetine,
citalopram and clomipramine) [RORadj:1 . 4 3( 9 5 %C I :1 . 1 1 –
1.83)], cluster 2 (amitriptyline, doxepin and imipramine)
[RORadj: 1.91 (95% CI: 1.30–2.81)] and cluster 3 (maproti-
line, nortriptyline, mianserin and mirtazapine) [RORadj:1 . 9 3
(95% CI: 1.32–2.83)] were positively associated with hyper-
glycaemia. The association was most pronounced for anti-
depressants from cluster 2 and cluster 3 with corresponding
binding properties for the 5-HT2c receptor, H1 receptor,
respectively, norepinephrinic (NE) reuptake transporter.
Also, there is support for a different association of hyper-
glycaemia and antidepressants in cluster 1 compared with
antidepressants in clusters 2 or 3 because the point estimates
for antidepressants in cluster 2 or 3 are not included in
the confidence interval for cluster 1 antidepressants. No
association was found between hyperglycaemia and anti-
depressants from cluster 4 (trazodone). The association of
hyperglycaemia was most pronounced after more than 1 year
of antidepressant use [RORadj: 2.05 (95% CI: 1.27–3.31)].
Antipsychotics were associated with a more than sixfold
increased risk of hyperglycaemia [RORadj:6 . 4 0( 9 5 %C I :
5.11–7.99)].
Hypoglycaemia
The base cohort consisted of 190,864 reports. From this
cohort, 525 (0.28%) reports were identified as cases and
190,339 (99.72%) as controls. Table 3 describes details of
demographic and medical characteristics of the study
population. Mean age was statistically significantly higher
among cases than among controls. Male and female were
equally divided among the cases and controls. The use of
diabetic medication, use of hyper- or hypoglycaemia-
inducing comedication was more frequently reported in
cases than in controls. Finally, cases were more frequently
reported within the period 2001–2005 than were controls.
Table 4 shows the association between the use of anti-
depressants and hypoglycaemia. Use of antidepressants was
associated with hypoglycaemia [RORadj: 1.84 (95% CI:
1.04–2.42)]. Looking at classification according to the phar-
macological properties of antidepressants, antidepressants
from cluster 1 (sertraline, fluvoxamine, paroxetine, venla-
faxine, fluoxetine, citalopram and clomipramine) [RORadj:
2.00 (95% CI: 1.51–2.65)] and cluster 2 (amitriptyline,
doxepin and imipramine) [RORadj: 2.19 (95% CI: 1.44–
3.33)], with corresponding binding properties for the sero-
tonin reuptake transporter, were positively associated with
hypoglycaemia. No association was found between hypo-
glycaemia and antidepressants from cluster 3 (maprotiline,
nortriptyline, mianserin and mirtazapine) and cluster 4
(trazodone). The association between hypoglycaemia and
the use of antidepressants from cluster 1 or 2 and anti-
Table 2 Risk of hyperglycaemia associated with use of psychotropic drugs
Risk factor Cases (hyperglycaemia)
(n=1953)
Controls (no hyperglycaemia)
(n=190,339)
ROR crude (95% CI) ROR adjusted * (95% CI)
Psychotropic agents
Benzodiazepines 86 (4.4%) 32,487 (17.1%) 1.00 (Reference) 1.00 (Reference)
Antidepressants 412 (21.1%) 101,198 (53.2%) 1.54 (1.22–1.94) 1.52 (1.20–1.93)
Antipsychotics 1,455 (74.5%) 56,654 (29.8%) 9.70 (7.80–12.06) 6.40 (5.11–7.99)
Antidepressant use (classification according to pharmacological properties)
Benzodiazepines 86 (17.3%) 32,487 (24.3%) 1.00 (Reference) 1.00 (Reference)
Cluster 1 AD 296 (59.4%) 74,931 (56.1%) 1.49 (1.17–1.90) 1.43 (1.11–1.83)
Cluster 2 AD 37 (7.4%) 8,541 (6.4%) 1.64 (1.11–2.41) 1.91 (1.30–2.81)
Cluster 3 AD 39 (7.8%) 8,230 (6.2%) 1.79 (1.23–2.62) 1.93 (1.32–2.83)
Cluster 4 AD 6 (1.2%) 2,314 (1.7%) 0.98 (0.43–2.24) 1.07 (0.47–2.45)
2 antidepressants 34 (6.8%) 7,182 (5.4%) 1.79 (1.20–2.66) 1.64 (1.10–2.44)
Duration of antidepressant use
Benzodiazepines 86 (33.2%) 32,487 (40.2%) 1.00 (Reference) 1.00 (Reference)
0–1 year 151 (58.3%) 44,649 (55.2%) 1.28 (0.98–1.67) 1.29 (0.98–1.69)
> 1 year 22 (8.5%) 3,738 (4.6%) 2.22 (1.39–3.56) 2.05 (1.27–3.31)
ROR reporting odds ratio, CI confidence interval, AD antidepressants
Cluster 1 antidepressants: sertraline, fluvoxamine, paroxetine, venlafaxine, fluoxetine, citalopram, clomipramine, Cluster 2 antidepressants:
amitriptyline, doxepin, imipramine, Cluster 3 antidepressants: maprotiline, nortriptyline, mianserin, mirtazapine, Cluster 4 antidepressants:
trazodone
* Adjusted for age, gender, reporting year, hypo- or hyperglycaemia-inducing comedication
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estimates for antidepressants in cluster 1 or 2 are not included
in the CI for antidepressants in cluster 3. Antipsychotics were
not associated with a higher risk of hypoglycaemia [RORadj:
0.84 (95% CI: 0.60–1.19)].
Discussion
Overall, the use of antidepressants was associated with
hyperglycaemia [RORadj: 1.52 (95% CI: 1.20–1.93)] and
hypoglycaemia [RORadj: 1.84 (95% CI: 1.40–2.42)] com-
Table 4 Risk of hypoglycaemia associated with use of psychotropic drugs
Risk factor Cases (hypoglycaemia)
(n=525)
Controls (no hypoglycaemia)
(n=190339)
ROR crude (95% CI) ROR adjusted * (95% CI)
Psychotropic agents
Benzodiazepines 64 (12.2%) 32,487 (17.1%) 1.00 (Reference) 1.00 (Reference)
Antidepressants 370 (70.5%) 101,198 (53.2%) 1.86 (1.42–2.42) 1.84 (1.40–2.42)
Antipsychotics 91 (17.3%) 56,654 (29.8%) 0.82 (0.59–1.12) 0.84 (0.60–1.19)
Antidepressant use (classification according to pharmacological properties)
Benzodiazepines 64 (14.7%) 32,487 (24.3%) 1.00 (Reference) 1.00 (Reference)
Cluster 1 AD 298 (68.7%) 74,931 (56.1%) 2.02 (1.54–2.65) 2.00 (1.51–2.65)
Cluster 2 AD 34 (7.8%) 8,541 (6.4%) 2.02 (1.33–3.07) 2.19 (1.44–3.33)
Cluster 3 AD 14 (3.2%) 8,230 (6.2%) 0.86 (0.48–1.54) 0.89 (0.50–1.60)
Cluster 4 AD 7 (1.6%) 2,314 (1.7%) 1.54 (0.70–3.35) 1.62 (0.74–3.54)
2 antidepressants 17 (3.9%) 7,182 (5.4%) 1.20 (0.70–2.05) 1.16 (0.68–2.00)
Duration of antidepressant use
Benzodiazepines 64 (27.4%) 32,487 (40.2%) 1.00 (Reference) 1.00 (Reference)
0–1 year 155 (66.2%) 44,649 (55.2%) 1.76 (1.32–2.36) 1.73 (1.28–2.33)
> 1 year 15 (6.4%) 3,738 (4.6%) 2.04 (1.16–3.58) 1.84 (1.04–3.27)
ROR reporting odds ratio, CI confidence interval, AD antidepressants
Cluster 1 antidepressants: sertraline, fluvoxamine, paroxetine, venlafaxine, fluoxetine, citalopram, clomipramine, Cluster 2 antidepressants:
amitriptyline, doxepin, imipramine, Cluster 3 antidepressants: maprotiline, nortriptyline, mianserin, mirtazapine, Cluster 4 antidepressants:
trazodone
* Adjusted for age, gender, reporting year, hypo- or hyperglycaemia-inducing comedication
Table 3 Baseline characteris-
tics of the hypoglycaemia
study population
Risk factor Cases
(hypoglycaemia)
(n=525)
Controls (no
hypoglycaemia)
(n=190339)
P value
Mean age (years) 50.9 47.3 0.043
Age category
18–35 years 115 (21.9%) 57,220 (30.1%) Reference
36–55 years 216 (41.1%) 75,546 (39.7%) 0.002
>55 years 194 (37.0%) 57,573 (30.2%) <0.001
Gender
Male 207 (39.4%) 76,024 (39.9%) Reference
Female 318 (60.6%) 114,315 (60.1%) 0.811
Diabetic comedication
No diabetic comedication 336 (64.0%) 187,674 (98.6%) Reference
Insulin 128 (24.4%) 923 (0.5%) <0.001
Oral antidiabetics 50 (9.5%) 1,647 (0.9%) <0.001
Oral antidiabetics + insulin 11 (2.1%) 95 (0.0%) <0.001
Hypo- or hyperglycaemia-inducing comedication use
No comedication associated with hypo- or
hyperglycaemia
378 (72.0%) 150,112 (78.9%) Reference
Comedication associated with hypo- or
hyperglycaemia
147 (28.0%) 40,227 (21.1%) <0.001
Reporting year
1968–1990 69 (13.1%) 36,644 (19.3%) Reference
1991–2000 296 (56.4%) 102,266 (53.7%) 0.001
2001–2005 160 (30.5%) 51,429 (27.0%) <0.001
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glycaemia was most pronounced for antidepressants with
corresponding binding properties for the 5-HT2c receptor,
H1 receptor and NE reuptake transporter. The association of
hypoglycaemia, on the other hand, was most pronounced
for antidepressants with corresponding binding properties
for the serotonin reuptake transporter.
Hyperglycemia is primarily a symptom of diabetes mel-
litus and a result of absolute or relative insulin deficiency.
Nondiabetic hyperglycaemia can be caused by eating dis-
orders, acute stress (such as stroke or myocardial infarction)
and the use of certain medications [19], particularly in
prediabetic patients. Evidence from trials of antidepressant-
associated hyperglycaemia in human is scarce. Moosa et al.
randomised a group of nondiabetic depressed women using
imipramine and fluoxetine for 3 months. In the imipramine
group, body mass index (BMI) increased and insulin
secretion and insulin resistance decreased during follow-
up [5]. Lustman et al. studied a group of diabetic patients
treated with nortriptyline for 8 weeks. Nortriptyline
worsened glycaemic control, whereas depression improve-
ment had an independent beneficial effect on glycated
haemoglobin (HbA1C), which is an aggregate measure of
glycaemic control over the 120-day period before testing
[20]. Laimer et al. observed a group of nondiabetic
depressed women treated with mirtazapine for 6 weeks.
They found that treatment with mirtazapine was associated
with a significant increase in body weight, body fat mass
and leptin concentration [21].
We found that the association between hyperglycaemia
and use of antidepressants was most pronounced for anti-
depressants from cluster 2 and cluster 3 with corresponding
binding properties for the NE reuptake transporter, 5-HT2c
receptor and H1 receptor. From a pharmacological point of
view, inhibition of the NE reuptake transporter increases
synaptic NE disposal directly by stimulating glycogenolysis
and gluconeogenesis, resulting in raised blood glucose
levels [22]. It is also postulated that central blockade of the
H1 receptor and 5-HT2c receptor stimulates energy intake
by increasing appetite with a resultant positive energy
balance, thereby causing weight gain [23–25]. Weight gain
may result in insulin resistance and increase the risk of
hyperglycaemia. Some of the antidepressants from cluster 2
and cluster 3 also have high affinity for the M3-, and α-1-
adrenergic receptors, causing side effects such as a dry
mouth, leading to drinking large quantities of (high-calorie)
soft drinks. Both effects on food intake may influence the
diabetic’s ability to follow a controlled diet. In addition,
peripheral blockade of M3 receptors in beta cells results in
suppression of insulin secretion and raised leptin levels
(also inhibiting insulin secretion by the pancreas), thereby
increasing the risk of hyperglycaemia [5, 26].
In general, hypoglycaemia can be caused by regulatory,
enzymatic or substrate defects. Iatrogenic hypoglycaemia
in patients with diabetes mellitus can be seen as the result
of the interplay of relative or absolute therapeutic insulin
excess and compromised glucose counterregulation [22],
and attenuation of warning signals can contribute to hypo-
glycaemia. Insulin excess, for example, occurs when sensi-
tivitytoinsulinisincreasedorendogenousglucoseproduction
is decreased. In different studies in patients with type 2
diabetes mellitus and nondiabetic patients, the use of
fluoxetine and the serotonergic anorectic agent fenfluramine
increased insulin sensitivity in the short term, thereby
increasing the risk on hypoglycaemia [27–31]. We found that
the association between hypoglycaemia and the use of anti-
depressants was most pronounced for antidepressants from
cluster 1 and cluster 2 with corresponding binding properties
for the serotonin reuptake inhibitor. These findings corre-
spond with earlier observations that serotonergic agents may
cause hypoglycaemia.
This study has several limitations. First, it could be
biased by confounding by indication. We did not have
information concerning the indications for use of the drugs.
Therefore, we were not able to identify whether hyper- or
hypoglycaemia was caused by a pharmacological effect of
antidepressants or by underlying diseases (i.e. depression).
It is known that depressive symptom severity in diabetic
patients is a risk factor for poor glycaemic control, generally
characterised by higher glucose levels [32, 33]. There is
evidence that recovery from depression improves glycaemic
control, not by inducing severe hypoglycaemic reactions but
by slight decreases in HbA1C. In two placebo-controlled
randomised clinical trials [34, 35] and one open study [36],
depressed diabetic patients were treated with fluoxetine,
paroxetine and sertraline, respectively, for 8–10 weeks. After
the study period, the treatment groups showed a trend
towards a better glycaemic control expressed as a decrease in
HbA1C. These studies, however, were not designed to reveal
the mechanism and to distinguish between a depression-
related effect or a pharmacological effect of antidepressants.
Second, cases are likely based on more pronounced symp-
tomatic episodes of hyper- and hypoglycaemia. Episodes of
asymptomatic hyper- or hypoglycaemia, or hyper- or hypo-
glycaemia self-treated by injection of insulin or intake of
carbohydrates or injection of glucagon are likely to go
unreported. To elucidate what happens on the microlevel
and in the short term, studies with more sensitive markers are
needed; for example, by analysing dosing patterns of insulin
and oral antidiabetics from diabetic diaries in patients starting
antidepressant treatment.
Third, we did not have explicit information about the
type of diabetes, which it is known to be an important risk
factor for hyper- and hypoglycaemia. We took into account
536 Eur J Clin Pharmacol (2008) 64:531–538patient age and the type of diabetic medication used. The
use of diabetic medication, however, was not completely
recorded. Sensitivity analysis with or without adjustment for
diabetic medication did not change the overall outcomes.
Fourth, ADRs were reported on a voluntary basis and
represent only a fraction (<10%) of the actual adverse events
that occurred [37, 38]. ADRs more likely to be reported
than others, if they are, include: (1) severe ADRs (which is
discussed above), (2) ADRs not listed in the summary of
product characteristics and (3) ADRs of relatively new drugs
[37, 39]. To adjust for possible time trends of reporting,
we included the reporting year in our multivariate logistic
regression model.
Fifth, the classification model of antidepressants based
on pharmacological properties deals with several restric-
tions. In the model, it is assumed that all antidepressants are
full agonists or antagonists for all receptor types and the
model does not account for active metabolites. However, in
contrast to the classical classification of antidepressants,
this pharmacodynamic classification system provides a
rational and objective basis in pharmacovigilance in the
search for high-risk antidepressants for specific ADRs and
may help unravel the mechanism behind these ADRs.
Finally, the inclusion of reports where the drug was
reported as interacting may be questionable, since this term
is often used for pharmacokinetic drug interactions and
would therefore have less relevance for a pharmacodynamic
effect of the drug. The reporter, however, may not always be
aware of a possible association between the use antidepres-
sants and disturbances in glucose homeostasis and therefore
classify the antidepressant as an interacting or concomitant
drug for an ADR. We therefore included all reports of drugs
classified as suspected, interacting or concomitant for an
ADR. Separate analyses for the suspected ADRs were
performed, but this did not change the overall outcome.
The strength of this study is that this is the first
controlled study to assess the association between anti-
depressant use and hyper- and hypoglycaemia in a large
population based upon spontaneous reporting in medical
practice. We were able to identify antidepressants that were
more likely to cause hyper- and hypoglycaemia. Finally, we
compared the association between antidepressant use and
hyperglycaemia with the association between antipsychotic
use and hyperglycaemia, which is a well-established and
clinically relevant side effect of antipsychotics.
In conclusion, the results of this study strengthen the
findings of individual case reports that the use of anti-
depressants is associated with disturbances in glucose
homeostasis. The association between antidepressant use
and hyperglycaemia was most pronounced for antidepres-
sants with high affinity for the NE reuptake transporter,
5-HT2c receptor and H1 receptor. The association was less
strong, however, compared with the reporting of hyper-
glycaemia associated with antipsychotics. The association
between antidepressant use and hypoglycaemia, on the
other hand, was most pronounced for antidepressants, with
a high affinity for the serotonin reuptake transporter. It is
important for diabetic patients to know that the use of
antidepressants can inadvertently interfere with strict blood
glucose self-monitoring and may precipitate or worsen epi-
sodes of either hyper- or hypoglycaemia. A follow-up study
is needed to confirm the associations we found in our study
and to translate these associations to the risk of antidepres-
sants on disturbances in glucose homeoastasis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution NonCommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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